PMID

Data

Article Title

Organization

Discovery of Highly Selective Inhibitors of the Immunoproteasome Low Molecular Mass Polypeptide 2 (LMP2) Subunit.

Kezar Life Sciences

Structure-based design of฿1i or฿5i specific inhibitors of human immunoproteasomes.

Leiden Institute of Chemistry and Netherlands Proteomics Centre

Structurally novel highly potent proteasome inhibitors created by the structure-based hybridization of nonpeptidic belactosin derivatives and peptide boronates.

Hokkaido University

Identification of N, C-capped di- and tripeptides as selective immunoproteasome inhibitors.

Chinese Academy of Medical Sciences and Peking Union Medical College

Metabolism guided optimization of peptidomimetics as non-covalent proteasome inhibitors for cancer treatment.

Zhejiang University

Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (?5i).

Merck

Cell-based screening of extracts of natural sources to search for inhibitors of the ubiquitin-proteasome system and identification of proteasome inhibitors from the fungus Remotididymella sp.

Kumamoto University

Discovery of Novel Quinoline-Based Proteasome Inhibitors for Human African Trypanosomiasis (HAT).

Novartis Institutes For Biomedical Research

Discovery of Anticancer Agents of Diverse Natural Origin.

University of Illinois At Chicago

Natural products from mangrove sediments-derived microbes: Structural diversity, bioactivities, biosynthesis, and total synthesis.

Chinese Academy of Sciences

Macrocyclic Peptides that Selectively Inhibit the

Weill Cornell Medicine

Development of peptide epoxyketones as selective immunoproteasome inhibitors.

Zhejiang University

Macrocyclic Immunoproteasome Inhibitors as a Potential Therapy for Alzheimer's Disease.

University of Kentucky

Structure-Based Design of Selective LONP1 Inhibitors for Probing

Genomics Institute of The Novartis Research Foundation

Discovery of novel tripeptide propylene oxide proteasome inhibitors for the treatment of multiple myeloma.

Nanjing Normal University

Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome.

The University of Melbourne

Discovery of Fluoromethylketone-Based Peptidomimetics as Covalent ATG4B (Autophagin-1) Inhibitors.

Roche Pharma Research and Early Development

Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.

Hangzhou Institute of Innovative Medicine

Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 S,3 R)- N-(( S)-3-(Cyclopent-1-en-1-yl)-1-(( R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-(( S)-2-(2-morpholinoacetamido)propanamido)propenamide).

Kezar Life Sciences

Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.

Hangzhou Xixi Hospital

Analysis of chain length, substitution patterns, and unsaturation of AM-404 derivatives as 20S proteasome stimulators.

Purdue University

Structure-Based Design of Inhibitors Selective for Human Proteasome ?2c or ?2i Subunits.

Leiden Institute of Chemistry and Netherlands Proteomics Centre

Novel Cell-Penetrating Peptide Conjugated Proteasome Inhibitors: Anticancer and Antifungal Investigations.

University of Auckland

Tetradehydrohalicyclamine B, a new proteasome inhibitor from the marine sponge Acanthostrongylophora ingens.

Kumamoto University

Cinnabaramides A-G: analogues of lactacystin and salinosporamide from a terrestrial streptomycete.

Intermed Discovery Gmbh (Imd)

Structure-based design of derivatives of tyropeptin A as the potent and selective inhibitors of mammalian 20S proteasome.

Numazu Bio-Medical Research Institute

Potent inhibitors of proteasome.

Cephalon

Structure-based optimisation of 2-aminobenzylstatine derivatives: potent and selective inhibitors of the chymotrypsin-like activity of the human 20S proteasome.

Novartis Pharma

Structure-based design of human immuno- and constitutive proteasomes inhibitors.

Universit£

Reviewing Hit Discovery Literature for Difficult Targets: Glutathione Transferase Omega-1 as an Example.

Monash University

Potent and Highly Selective Inhibitors of the Proteasome Trypsin-like Site by Incorporation of Basic Side Chain Containing Amino Acid Derived Sulfonyl Fluorides.

University of Glasgow